	US 12,295,955 B2
	TTP phosphorylation for the identification of personalized medicines
Khalid S. Abu Khabar, Riyadh (SA)
Assigned to King Faisal Specialist Hospital & Research Centre, Riyadh (SA)
Filed by KING FAISAL SPECIALIST HOSPITAL & RESEARCH CENTRE, Riyadh (SA)
Filed on Mar. 10, 2023, as Appl. No. 18/181,890.
Application 18/181,890 is a division of application No. 16/710,455, filed on Dec. 11, 2019, granted, now 11,648,251.
Prior Publication US 2023/0310437 A1, Oct. 5, 2023
Int. Cl. A61K 31/519 (2006.01); A61K 31/517 (2006.01); A61K 45/06 (2006.01); A61P 35/00 (2006.01); G01N 33/50 (2006.01); G01N 33/574 (2006.01); G01N 33/68 (2006.01)

CPC A61K 31/519 (2013.01) [A61K 31/517 (2013.01); A61K 45/06 (2013.01); A61P 35/00 (2018.01); G01N 33/5011 (2013.01); G01N 33/57484 (2013.01); G01N 33/6893 (2013.01); G01N 2800/52 (2013.01)]

9 Claims

1. A method of identifying a targeted therapy compound selected from protein kinase inhibitors, small molecule inhibitors, and monoclonal antibody-based compounds for personalized medicine, wherein said targeted therapy compound is for precision cancer therapy of a cancer patient, said method comprising, in any order, the following steps:

a) obtaining a tumor sample from a patient,

b) optionally, determining a level of phosphorylated TTP in said tumor sample,

c) providing one or more targeted therapy compound(s) to be tested,

d) treating said tumor sample with said one or more targeted therapy compound(s),

e) determining whether said one or more targeted therapy compound(s) reduce(s) the levels of phosphorylated TTP in said treated sample compared to a control,

wherein a reduction in the level of phosphorylated TTP indicates that said one or more targeted therapy compound(s) is/are effective for treating said patient.